Tenax Therapeutics, Inc.
TENX Real Time Price USDRecent trades of TENX by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by TENX's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (ph-hfpef) Apr. 30, 2024
-
Patent Title: Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (ph-hfpef) Jul. 18, 2023
-
Patent Title: Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (ph-hfpef) Mar. 21, 2023
-
Patent Title: Pharmaceutical compositions for subcutaneous administration of levosimendan Jan. 04, 2022
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of TENX in WallStreetBets Daily Discussion
Recent insights relating to TENX
Recent picks made for TENX stock on CNBC
ETFs with the largest estimated holdings in TENX
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view TENX Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.